Healthcare Equipment and Supplies
Company Overview of Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical device company, focuses on the design, development, and commercialization of various products for people with insulin-dependent diabetes in the United States. The company offers t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set; t:connect diabetes management application, a PC and Mac-compatible cloud-based data management application that provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and t:flex insulin delivery system that includes 480-unit disposable insulin cartridge and ...
11045 Roselle Street
San Diego, CA 92121
Founded in 2006
Key Executives for Tandem Diabetes Care, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $532.7K
Chief Financial Officer and Treasurer
Total Annual Compensation: $362.6K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $347.1K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $347.1K
Chief Administrative Officer
Total Annual Compensation: $275.2K
Compensation as of Fiscal Year 2014.
Tandem Diabetes Care, Inc. Key Developments
Tandem Diabetes Care, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year Ending December 31, 2015
Apr 30 15
Tandem Diabetes Care, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported sales of $12,308,000 compared to $8,065,000 a year ago. Operating loss was $20,410,000 compared to $20,838,000 a year ago. Net loss was $21,208,000 or $0.83 per basic and diluted share compared to $21,962,000 or $0.96 per basic and diluted share a year ago. Operating loss included non-cash, stock-based compensation of $3.8 million for the quarter ended March 31, 2015, which was the same as the comparable period of 2014.
For the year ending December 31, 2015, the Company affirms its prior guidance as follows: Sales are estimated to be in the range of $70.0 million to $75.0 million, which includes $1.0 million to $3.0 million of t:flex Insulin Pump sales; Operating margin is estimated to be in the range of negative 100% to negative 110%, which includes approximately $13.0 million to $14.0 million in non-cash, stock-based compensation expense.
Tandem Diabetes Care, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 10:00 AM
Apr 23 15
Tandem Diabetes Care, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 10:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Kim D. Blickenstaff, Chief Executive Officer, President and Director.
Tandem Diabetes Care, Inc. Commences Shipping t:slim Insulin Pump with Updated Software
Apr 20 15
Tandem Diabetes Care, Inc. commenced shipments of t:slim Pumps featuring enhanced software. The updated software, based on customer and healthcare provider feedback, includes an expansion of the reverse correction function, the ability to enter a manual bolus directly in the suggested bolus window, off-pump cartridge filling, and other features to enhance convenience and flexibility. Tandem is actively working on a project to provide current t:slim Pump users the ability to update their pump software remotely, similar to other modern consumer devices. The company plans to submit a filing for this remote update capability to the U.S. Food and Drug Administration later in 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|